Novel cyclopropenes for studying biological systems

A Thesis Presented

by

Sining Li

to

The Graduate School

in Partial Fulfillment of the

Requirements

for the Degree of

Master of Science

in

Chemistry Program

(Concentration – optional)

Stony Brook University

August 2017
Stony Brook University
The Graduate School

Sining Li

We, the thesis committee for the above candidate for the Master of Science degree, hereby recommend acceptance of this thesis.

Dr. Scott Laughlin
Assistant Professor, Chemistry

Dr. Kathlyn Parker
Professor, Chemistry

Dr. Isaac Carrico
Associate Professor, Chemistry

This thesis is accepted by the Graduate School

Charles Taber
Dean of the Graduate School
Abstract

Novel cyclopropenes for studying biological systems

by

Sining Li

Master of Science

in

Chemistry Program

Stony Brook University

August 2017

Click and bioorthogonal chemistry has been employed in the analysis of many biological systems, but has yet to be extended to the analysis of neural connectivity\(^1\). One popular bioorthogonal chemical reporter is the functionalized cyclopropene, which reacts with tetrazines through an inverse electron-demand Diels-Alder reaction\(^2\). Here, I describe a strategy for leveraging the cyclopropene-tetrazine ligation for analysis of neural systems and a novel photo-activatable cyclopropene for controlling reactivity in space and time. My first project employs a dopamine analog consisting of a neurotransmitter attached to a cyclopropene tag to study the dopaminergic neural circuit. I designed and synthesized three different cyclopropene-bearing dopamine analogs. These molecules will enable visualization of dopaminergic vesicles and connected neurons, when they are released into the synaptic space. My second project involves developing a new, activatable, bio-orthogonal reagent. I have synthesized a spirocyclopropene that is non-reactive when protected with a light cleavable group, but reactive towards tetrazine reagents once the group is removed by light. Ultimately, this strategy will enable controlled bioorthogonal reactivity that will permit the development of imaging tools for visualizing neural connectivity.
Table of Content

Chapter I: Novel cyclopropene-modified dopamine for analyzing dopaminergic neural systems ................................................................................................................................. 1

   Introduction ............................................................................................................................................................................. 1

   Synthesis of cyclopropene-containing dopamine analogs ........................................................................................................... 6

   Experiment section .................................................................................................................................................................... 10

       General materials and methods ........................................................................................................................................ 10

       General method 1 to remove TMS group .................................................................................................................................. 11

       General method 2 to remove Boc group ................................................................................................................................ 11

       Method for synthesis dopamine analog ............................................................................................................................. 11

       NMRs for the molecules synthesized in chapter I ................................................................................................................. 19

Chapter II: Development of spirocyclopropene, a new chemical biology tool to control cyclopropene reactivity .......................................................................................................................... 41

   Introduction ............................................................................................................................................................................. 41

   Synthesis of 3-N-substituted spirocyclopropenes .................................................................................................................... 42

   Synthesis of photoactivatable di-fluoro spirocyclopropene ........................................................................................................ 45

   Experiment section .................................................................................................................................................................... 45

       General materials and methods ........................................................................................................................................ 45

       NMRs for the molecules synthesized in chapter II............................................................................................................... 46
Chapter I: Novel cyclopropene-modified dopamine for analyzing dopaminergic neural systems

Introduction

The neural circuitry of the human brain is still not clearly understood. However, understanding neural circuitry of smaller brain systems, for example, the olfactory system, can provide information that can be extrapolated to more complex system to inform our understanding of neurodegenerative diseases like Parkinson’s and Alzheimer's Disease.

In the past two decades, the development of click chemistry and bioorthogonal chemistry supplies several new methods for visualizing living systems. Here, I describe a strategy for visualizing neural systems based on the cyclopropene-tetrazine ligation (Figure 1). Essentially, I have designed and synthesized reactive molecules that can react with profluorescent tetrazines in synaptic vesicles and the synaptic cleft to generate a fluorescent compound, which will enable imaging neural circuitry. These two reactive molecules are a cyclopropene-modified neurotransmitter and a pro-fluorescent lipid at the post-synaptic membrane.

Neurons never function in isolation, usually neurons are organized into circuits which process the specific kinds of information. Neural circuits varies greatly because of the different intended function. In order to figure out the neural circuits for the certain function and reveal how the
neural circuits affects disease generation, different molecular imaging methods have been
developed in the past few years. Recent popular strategies for visualizing neural connectivity use
protein based fluorescent probes, PET and MRI\(^3\).

Fluorescent probes are widely used in biological systems like flies, mice and larval zebrafish.
Some of the probes are also employed in studying neural systems. Protein based fluorescent
probes and small molecule based fluorescent probes are the most popular tools for studying
neural circuits.

Protein based fluorescent probes are usually the sensor of Ca\(^{2+}\) signals. Ca\(^{2+}\) signals can be
widely detected in neural systems, ranging from complex neuronal networks to individual
synapse. Therefore, imaging Ca\(^{2+}\) signals has become a popular method to analyze complex
neural systems, especially olfactory receptor neurons. By measuring the kinetics of Ca\(^{2+}\)
response, people can track the neuronal activity. As the powerful tools to detect Ca\(^{2+}\) signals,
genetically encoded fluorescent calcium indicator proteins (FCIPs) have been employed in both
vivo and vitro for Ca\(^{2+}\) imaging. FCIPs have many advantages including noninvasive loading
procedure, application for long-term studies and the ability to target selected neurons\(^3\). Camgaroo
(Camgaroo-1 and Camgaroo-2) is one of variant of yellow emitting fluorescent proteins (YFP). It
has been used to image calcium signal in Drosophila mushroom bodies to study its roles in
olfactory learning and memory\(^4\). G-CaMP, another Ca\(^{2+}\)-sensitive probe, been successfully used
to image populations of glomerular activity in the Drosophila antennal lobe presynaptically or
postsynaptically expressed in ORNs or in projection neurons\(^5\). However, the measurement
requires careful interpretation and several control experiments. Better specificity, enhanced
photostability is still needed.
Small molecule based fluorescent probes have been rapidly developed in the past years. Ca\(^{2+}\) sensitive dyes has been developed and employed in neural systems because of its stable and strong fluorescent signal, especially the voltage-sensitive dyes which have been reported to image the olfactory systems, such as Di8-ANEPPQ which label anterogradely at afferent axons of olfactory receptor neurons in zebrafis\(^6\) and VoltageFluors\(^7\) which detect synaptic and action potentials in cultured hippocampal neurons. However, the restriction of the Ca\(^{2+}\) sensitive dyes is that the background fluorescence is so strong, since some of the dyes can be uptake into all plasma membranes nonspecifically. It can obscure the boundary between the stained cells, make it difficult to tell the fluorescence changes against a high background of nonexcitable stained cells. The background signal can easily miss up the imaging.

PET imaging has been rapidly developed. It is also a popular method to investigate neural systems and it has been proved to be an advanced neuroimaging technique. PET usually employs the radioactive probe containing an isotope such as carbon-11, nitrogen-13 and fluorine-18. PET imaging can directly reflect the change of cerebral blood flow. Among the several radionuclides, H\(_2\)\(^{15}\)O is widely used, because it can reflect the regional cerebral blood flow (rCBF), for example, \([^{15}\text{O}]\text{butanol-PET}\) has been used to detect rCBF during monorhinic presentations. \(^{18}\text{F}\) is another popular radionuclide, \(^{18}\text{F-FDG-PET}\) has been used to study glucose metabolism in olfactory systems. Yet the resolution of the PET imaging is 1 mm which is relatively lower. This strategy can’t be used to image a single synapse and reveal the connection between single neuron cells.

Compared with PET imaging, MRI probes has many advantages including high spatial resolution, long storage period, and low toxic labels. All of the advantages make MRI have a promising impact on imaging neural system. MRI has been employed to diagnose the injury of
brain soft tissues. However, many of the MRI probes have the problem to break the Blood-Brain Barrier. Even though some MRI probes have been successfully employed to investigate the neutral systems and get a high spatial resolution imaging, a new, general imaging technique with high resolution is still needed for studying neural circuits and cell-cell connection.

Another promising strategy to mapping neural circuit is using neurotropic viruses, like vesicular stomatitis virus\(^8\) and rabies virus\(^9\). These kinds of viruses can travel through cell to cell via synapse so that they have been engineered to become tracers that can reveal the neural circuits and cell-cell connectivity in high resolution. However, these strategies are best suitable to the retrograde direction and viruses can be toxic. These strategies are not applicable in fixed systems, such as in embryonic development and the post-mortem human nervous system.

Because of the all the weakness, my group try to find a new method to study neural circuits with high spatial and temporal precision. The research of our group is trying to develop a novel class of the trans-synaptic tracer which can be used to image neural circuits and visualize functional cell-cell interactions. Our strategy employs click chemistry and try to design and synthesis neurotransmitters that contain a cyclopropene tag and target it to the synapse where they will react with a biorthogonal partner to trigger fluorescence and image the synapse. Next we deliver neurotransmitter analogs to the interested part of brain or engineered cells through microinjection.

Because the neurotransmitter analogs have the similar structure of the essential neurotransmitter, we hypothesize that analogs can be packaged into synaptic vesicles by vesicular transporters and released at the synapse in neurons. Once the analogs packaged into synaptic vesicles or released at the synapse, they will react with pro-fluorescent tetrazine and trigger the fluorescence. By this
way, we can image the neural circuits. We also can visualize the location of different types of synaptic vesicles by this technique. We hope this technique will be a novel method to study neuroscience and conquer the disadvantages of the current methods mentioned above.

My work focuses on dopaminergic neural systems. Recent research has revealed that dopaminergic neural systems are related to many neural degenerative diseases\textsuperscript{10,11,12}. Yet, the detailed mechanism is still unclear. I hope my research will be helpful. I have synthesized cyclopropene-modified dopamine analogs that can react with a tetrazine group. The molecules I have made will help reveal dopaminergic neural circuitry and provide details about normal and pathological brain function.

In past work, Dalibor Sames and co-workers has developed a notable dopamine analog, FFN511\textsuperscript{13}. FFN511 is a fluorescent false neurotransmitters. Sames used FFN511 to observe the uptake and release of neurotransmitter from the individual presynaptic terminals. It has proved to be concentrated in dopaminergic vesicles and can be released at the synapse. During the experiments, Sames found that ethylene amine part was important for recognition by monoamine transporters. Dopamine, serotonin, and norepinephrine can be concentrated into synthetic vesicles by vesicular mono-amine transporter 2 (VMAT2) because of the ethylene amine part. Based on this point and the structure of dopamine, I have synthesized three cyclopropene analogs which are highly similar to dopamine. Current efforts focus on employing this neurotransmitter analogs in cultured dopaminergic neurons and larval zebrafish
Synthesis of cyclopropene-containing dopamine analogs

I have designed and synthesized three different dopamine analogs. All the analogs have two parts, the cyclopropene and the substituted dopamine structure (Figure 2). All the dopamine analogs are very similar to the original dopamine and they all contain the ethylene amine part, which is important for recognizing by monoamine transporter.

For synthesis of the analogs, two kinds of intermediates are necessary, one is the intermediate

![Figure 3: Structure of dopamine analog](image)

![Figure 2: scheme for cyclopropene intermediate I](image)

![Figure 4: scheme for cyclopropene intermediate II](image)

for cyclopropene, and the other one is the intermediate for substituted dopamine. I designed and
synthesised two different kinds of cyclopropene intermediate. The first one is an active ester (Figure 3), which is highly reactive with amines. However, several previous reports have noted that an electron withdrawing group on the C-3 carbon may lower the reaction rate of the cyclopropene-tetrazine ligation. Thus, I designed another cyclopropene intermediate, which is linked to the dopamine scaffold via an amine (Figure 4) and should be faster than the more electron withdrawing ester.

The other important part of the analogs is the substituted dopamine (Figure 5). The structure of the substituted dopamine is very similarly to the original dopamine. I have made three different kinds of substituted dopamine (Figure 6), amino substituted dopamine, aldehyde substituted dopamine, and active ester substituted dopamine. The synthesis for all the substituted dopamines begins with tyramine and use different coupling methods to assemble the dopamine analogs (Figure 6).
Now all the dopamine analogs are available, and we have already test the kinetic of dopamine analog C. The kinetic experiment gives us a very promising data that our molecules can rapidly react with tetrazine in vivo and image the neural circuit.

Next, we will test dopamine analogs A-C in dopaminergic neurons with a pro-fluorescent tetrazine to make sure that the dopamine analogs can concentrate in dopaminergic vesicles (Figure 7). This tetrazine quenches fluorescence, which means when we connect the fluorophore with tetrazine, the molecule becomes non-fluorescent\(^\text{14}\). When the cyclopropene analogs react with tetrazine, the products of the reaction become fluorescence again. We will inject our analogs and tetrazine into dopaminergic neurons and use confocal microscopy to detect the signal of the
fluroescence and evaluate how efficient the analogs can concentrate into the vesicles to identify
the best candidate for in vivo experiments.
Experiment section

General materials and methods. All chemical reagents were of analytical grade, obtained from commercial suppliers, and used without further purification unless otherwise specified. Rhodium (II) acetate (Rh$_2$OAc$_4$) was gently heated under vacuum until it became a free flowing powder (typically 15–20 s) before using it for reactions. Reactions were monitored by thin layer chromatography (TLC) on pre-coated glass TLC plates (Analtech UNIPLATE™ silica gel HLF w/ organic binder, 250 μm thickness, with UV254 indicator) or by LC/MS (Agilent LC-MSD, direct-injection mode, 1–10 μL, ESI). TLC plates were visualized by UV illumination or developed with either potassium permanganate stain (KMnO$_4$ stain: 1.5 g KMnO$_4$, 10 g K$_2$CO$_3$ and 1.25 mL of 10% NaOH dissolved in 200 mL H$_2$O), ceric ammonium molybdate stain (CAM stain: 12 g (NH$_4$)$_6$Mo$_7$O$_{24}$ • 4H$_2$O, 0.5 g Ce(NH$_4$)$_2$(NO$_3$)$_6$ and 15 mL of concentrated H$_2$SO$_4$ dissolved in 235 mL H$_2$O), or ninhydrin stain (1.5 g ninhydrin dissolved in 100 mL of n-BuOH and 3 mL of conc. AcOH). Flash chromatography was carried out using Sorbtech, 60 Å, 40–63 μm or Millipore 60 Å, 35-70 μm silica gel according to the procedure described by Still$^{15}$. HPLC was performed using a Shimadzu HPLC (FCV-200AL) equipped with an Agilent reversed phase Zorbax Sb-Aq C18 column (4.6 × 250 mm or 21.2 × 250 mm) fitted with an Agilent stand-alone prep guard column. NMR spectra (1H and 13C) were obtained using a 400, 500, or 700 MHz Bruker spectrometer and analysed using Mestrenova 9.0. 1H and 13C chemical shifts (δ) were referenced to residual solvent peaks. High-resolution electrospray ionization (ESI) mass spectra were obtained at the Stony Brook University Institute for Chemical Biology and Drug Discovery Mass Spectrometry Facility with an Agilent LC-UV-TOF spectrometer.
General method 1 to remove TMS group. A solution of TMS protected compound (1 eq) in dry THF was added 1 M TBAF (1.2 eq) dropwise under N\textsubscript{2} at 0 °C. After 12h, the reaction mixture was diluted by water and DCM. The organic layer was combined, aqueous layer was further washed with DCM. The combined organic layers were dried over anhydrous Na\textsubscript{2}SO\textsubscript{4}, concentrated in vacuo, and purified by flash chromatography.

General method 2 to remove Boc group. A solution of boc protected compound was dissolved in 20% TFA/DCM (v/v) at 0 °C. After 1h the reaction mixture was directly concentrated in vacuo. The crude was dissolved in water and purified by HPLC

Method for synthesis dopamine analog

![Compound 1](image1)

Compound 1 was synthesized essentially as previously described\textsuperscript{16}. Tyramine (1.37 g, 10 mmol, 1 eq) was mixed with 30% HNO\textsubscript{3} (48 mmol, 4.8 eq). The resulting suspension was stirred at room temperature. The crude was diluted with water (20 mL) and applied onto a Dowex 50W-X2 (200–400 mesh) column (1.5 cm × 6 cm, H\textsuperscript{+} form, equilibrated with water). The column was washed with water (100 mL) and then the product was eluted with 2 M HCl (20 mL/fraction). Fractions containing the target compound were combined and evaporated to dryness to give a yellow powder. (210mg, 91%).

![Compound 2](image2)

A solution of 1 (915 mg, 5 mmol, 1eq) in H\textsubscript{2}O/THF (V/V=1:1), was added Boc\textsubscript{2}O (2.16 g, 10 mmol, 2 eq) and NaHCO\textsubscript{3} (1.8 g, 20 mmol 4 eq) at room temperature. After 12h, the reaction
mixture was diluted by water and DCM. The organic layer was combined, aqueous layer was further washed with DCM. The combined organic layers were dried over anhydrous Na$_2$SO$_4$, concentrated in vacuo, and purified by flash chromatography (30 g silica, 20% ethyl acetate/hexanes (v/v)) to obtain 2 (1.4 g, 99%). $^1$H NMR (500 MHz, Chloroform-d): $\delta$ = 10.50 (s, 1H), 7.94 (d, $J = 2.2$ Hz, 1H), 7.46 (dd, $J = 8.6, 2.2$ Hz, 1H), 7.13 (d, $J = 8.6$ Hz, 1H), 4.59 (s, 1H), 3.38 (q, $J = 6.6$ Hz, 2H), 2.82 (t, $J = 7.1$ Hz, 2H), 1.45 (s, 9H). $^{13}$C NMR (126 MHz, Chloroform-d): $\delta$ = 156.18, 142.85, 134.69, 131.50, 119.43, 116.99, 79.47, 115.36, 41.98, 35.49, 28.45.

A solution of 2 (282 mg, 1 mmol, 1 eq) in DCM was added 20 mg Pd/C under H$_2$ in room temperature. After 12h, the reaction mixture pass through celite to get rid of Pd/C. Combine the organic layer, concentrated in vacuo to give 252 mg 3 as light yellow powder (232mg,100%). $^1$H NMR (500 MHz, Chloroform-d): $\delta$ = 6.69 (d, $J = 7.9$ Hz, 1H), 6.58 (s, 1H), 6.47 (d, $J = 8.0$ Hz, 1H), 4.65 (s, 1H), 3.32 (t, $J = 7.0$ Hz, 2H), 2.65 (t, $J = 7.2$ Hz, 2H), 1.46 (s, 9H). $^{13}$C NMR (126 MHz, Chloroform-d): $\delta$ = 156.57, 143.23, 135.08, 131.88, 119.81, 117.37, 115.73, 77.67, 42.36, 35.86, 28.83.

A solution of tyramine (640 mg, 5 mmol, 1eq) in H$_2$O/THF (V/V=1:1), was added Boc$_2$O (2.16 g, 10 mmol, 2 eq) and NaHCO$_3$ (1.8 g, 20 mmol 4 eq) at room temperature. After 12h, the reaction mixture was diluted by water and DCM. The organic layer was combined, aqueous layer was further washed with DCM. The combined organic layers were dried over anhydrous Na$_2$SO$_4$, concentrated in vacuo, and purified by flash chromatography (30 g silica, 20% ethyl acetate/hexanes (v/v)) to obtain 4. (1.1 g, 99%). $^1$H NMR (500 MHz, Chloroform-d): $\delta$ = 7.07 (d, $J$
= 8.4 Hz, 2H), 6.84 – 6.74 (m, 2H), 4.56 (s, 1H), 3.36 (d, J = 7.2 Hz, 2H), 2.74 (t, J = 7.1 Hz, 2H), 1.46 (s, 9H).

A solution of 4 (460 mg, 2 mmol, 1 eq) in 2.4 ml 10 N NaOH was heated to 65 ℃. Then 2 ml of CH₃Cl was adding in 3 portions over 15 min. The mixture was heated at reflux in chloroform for 4h. After cooling, the mixture was acidified to pH 1 with 12 N HCl. The organic layer was combined, aqueous layer was further washed with DCM. The combined organic layers were dried over anhydrous Na₂SO₄, concentrated in vacuo, and purified by flash chromatography (25 g silica, 20% ethyl acetate/hexanes (v/v)) to obtain 5 (330 mg, 65%).

1H NMR (500 MHz, Chloroform-d): δ= 10.91 (s, 1H), 9.89 (d, J = 0.7 Hz, 1H), 7.39 (d, J = 8.0 Hz, 2H), 7.00 – 6.92 (m, 1H), 4.58 (s, 1H), 3.38 (q, J = 6.8 Hz, 2H), 2.81 (t, J = 7.1 Hz, 2H), 1.45 (s, 9H).

13C NMR (126 MHz, Chloroform-d): δ= 196.49, 160.27, 155.83, 137.63, 133.44, 130.46, 120.51, 117.84, 80.10, 41.70, 36.13, 28.40.

A solution of 5 (265 mg, 1 mmol, 1 eq) in 2 ml MeOH, was mixed with a solution of KMnO₄ (157 mg, 1 mmol, 1 eq) and Na₂HPO₄ (143 mg, 1 mmol, 1 eq) in H₂O (2 ml). The product stream was eluted into a stirred biphasic mixture prepared from 1 M HCl (3 ml) saturated with sodium chloride and sodium thiosulfate (20 mg) and EtOAc. The organic layer was combined, aqueous layer was further washed with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, concentrated in vacuo to provide 6 (252 mg, 91%).
A solution of 6 (100 mg, 0.35 mmol, 1 eq) in 2 ml dry DCM, was added PFP-TFA (120 mg, 0.42 mmol, 1.2 eq) and TEA (43 mg, 0.42 mmol, 1.2 eq). After 1h, the reaction mixture was diluted by water and DCM. The organic layer was combined, aqueous layer was further washed with DCM. The combined organic layers were dried over anhydrous Na$_2$SO$_4$, concentrated in vacuo, and purified by flash chromatography (6 g silica, 100 % DCM) to obtain 7 (125 mg, 80%). $^1$H NMR (500 MHz, Chloroform-d): 9.76 (s, 1H), 7.89 (d, J = 2.3 Hz, 1H), 7.47 (dd, J = 8.7, 2.2 Hz, 1H), 7.05 (d, J = 8.6 Hz, 1H), 4.66 (s, 1H), 3.40 (q, J = 6.6 Hz, 2H), 2.83 (t, J = 7.2 Hz, 2H), 1.45 (s, 9H).$^{13}$C NMR (126 MHz, Chloroform-d): δ = 166.01, 161.16, 156.09, 143.65, 142.36, 140.22, 138.83, 138.38, 137.00, 130.54, 130.26, 118.38, 109.64, 79.77, 41.74, 35.19, 29.71, 28.33.

Cyclopropene PFP ester was synthesized as previously described$^1$.

A solution of 2 (252 mg, 1 mmol, 1 eq) in 5 ml dry DMF was added cyclopropene PFP ester (290 mg, 1.1 mmol, 1.1 eq) under N$_2$ and heated to 50°C. After 24h, the reaction mixture was diluted by DCM and water. The organic layer was combined, aqueous layer was further washed with DCM. The combined organic layers were dried over anhydrous Na$_2$SO$_4$, concentrated in vacuo, and purified by flash chromatography (15 g silica, 45% ethyl acetate/hexanes (v/v)) to obtain 9 (282 mg, 85%). $^1$H NMR (500 MHz, CD3Cl): δ = 9.39
(s, 1H), 7.79 (s, 1H), 6.93 (m, 2H), 6.79 (s, 1H), 6.53 (s, 1H), 4.61 (s, 1H), 3.31 (q, 2H), 2.68 (t, 2H), 2.29 (d, 2H), 2.25 (d, 1H), 1.46 (s, 9H). $^{13}$C NMR (126 MHz, CDCl$_3$): δ = 176.66, 156.02, 147.38, 130.62, 127.09, 125.88, 122.00, 119.96, 113.49, 95.69, 79.41, 41.88, 35.20, 28.43, 22.85, 10.66.

Cyclopropene alcohol was synthesized as previously described.$^{17}$

![Cyclopropene alcohol](image)

Cyclopropene amine was synthesized as previously described.$^{17}$

![Cyclopropene amine](image)

A solution of 5 (70 mg, 0.26 mmol, 1 eq) in MeOH was added cyclopropene amine (70 mg, 0.45 mmol, 1.7 eq) at 0 ℃. After 1h, NaBH$_4$ (20 mg, 0.5 mmol, 1.8 eq) was add to the reaction mixture. After another 1h, the reaction was diluted with water and DCM, The combined organic layers were dried over anhydrous Na$_2$SO$_4$, concentrated in vacuo, and purified by flash chromatography (6 g silica, 40% ethyl acetate/hexanes (v/v), 1% TEA) to obtain 12 (73 mg, 70%). $^1$H NMR (500 MHz, CDCl$_3$): δ 6.98 (dd, J = 8.2, 2.2 Hz, 1H), 6.82 (s, 1H), 6.78 (d, J = 8.2 Hz, 1H), 4.55 (s, 1H), 3.97 (s, 2H), 3.39 – 3.30 (m, 2H), 2.71 (dt, J = 14.1, 5.7 Hz, 3H), 2.50 (dd, J = 11.9, 5.0 Hz, 1H), 2.23 (s, 3H), 1.50 (t, J = 4.7 Hz, 1H), 1.45 (s, 9H), 0.18 (s, 9H). $^{13}$C NMR (126 MHz, Chloroform-d):
\( \delta = 157.03, 155.92, 136.18, 128.97, 128.72, 128.51, 122.79, 116.35, 115.39, 112.05, 79.14, 58.67, 55.93, 52.54, 42.04, 35.27, 28.43, 27.98, 19.52, 13.39, -1.03. \)

Compound 13 was obtained by general method 2 from compound 9. \(^1\)H NMR (500 MHz, CDCl\(_3\)): \(\delta = 9.39\) (s, 1H), 7.79 (s, 1H), 6.93 (m, 2H), 6.79 (s, 1H), 6.53 (s, 1H), 4.61 (s, 1H), 3.31 (q, 2H), 2.68 (t, 2H), 2.29 (d, 2H), 2.25 (d, 1H). \(^{13}\)C NMR (126 MHz, CDCl\(_3\)): \(\delta = 178.04, 148.40, 128.73, 127.67, 126.45, 123.49, 117.13, 114.11, 96.39, 42.09, 33.96, 23.54, 10.66. \)

A solution of 7 (145 mg, 0.32 mmol, 1eq) in dry DMF was added cyclopropene amine (60 mg, 0.38 mmol, 1.2eq) and TEA (49 mg, 0.48mml, 1.5 eq) under N\(_2\). After 18h, the reaction mixture was diluted by DCM and water. The organic layer was combined, aqueous layer was further washed with DCM. The combined organic layers were dried over anhydrous Na\(_2\)SO\(_4\), concentrated in vacuo, and purified by flash chromatography (8 g silica,10 % ethyl acetate/hexanes (v/v)) to obtain 14 (80 mg, 60%). \(^1\)H NMR (500 MHz, Chloroform-d): \(\delta = 7.27 - 7.17\) (m, 2H), 6.92 (d, J = 8.4 Hz, 1H), 6.49 (d, J = 7.2 Hz, 1H), 4.65 (s, 1H), 3.47 – 3.33 (m, 3H), 3.25 (dt, J = 13.6, 5.3 Hz, 1H), 2.75 (t, J = 7.1 Hz, 2H), 2.24 (s, 3H), 1.58 (dd, J = 5.2, 4.4 Hz, 1H), 1.43 (s, 9H), 0.19 (s, 9H). \(^{13}\)C NMR (126 MHz, Chloroform-d): \(\delta = 169.54, 160.05, 158.05, 148.40, 137.86, 128.97, 128.72, 128.51, 122.79, 116.35, 115.39, 112.05, 79.14, 58.67, 55.93, 52.54, 42.04, 35.27, 28.43, 27.98, 19.52, 13.39, -1.03. \)
Compound 15 was obtained by general method 1

^1^H NMR (500 MHz, Chloroform-d) δ 12.35 (s, 1H), 7.27 − 7.17 (m, 2H), 6.93 (d, J = 8.4 Hz, 1H), 6.73 − 6.63 (m, 1H), 6.48 (s, 1H), 4.61 (s, 1H), 3.48 (ddd, J = 13.7, 5.7, 4.1 Hz, 1H), 3.40 (q, J = 6.9 Hz, 2H), 3.32 (dt, J = 13.7, 5.1 Hz, 1H), 2.77 (t, J = 7.2 Hz, 2H), 2.18 (d, J = 1 Hz, 3H), 1.69 (td, J = 4.4, 1.6 Hz, 1H), 1.45 (s, 9H). ^1^C NMR (126 MHz, Chloroform-d): δ= 169.79, 160.07, 156.09, 134.45, 128.57, 125.17, 121.51, 118.57, 114.42, 102.80, 79.45, 45.67, 41.34, 35.35, 28.41, 17.86, 11.61.

Compound 16 was obtained by general method 2.

^1^H NMR (500 MHz, Chloroform-d) δ 12.35 (s, 1H), 7.27 − 7.17 (m, 2H), 6.93 (d, J = 8.4 Hz, 1H), 6.73 − 6.63 (m, 1H), 6.48 (s, 1H), 4.61 (s, 1H), 3.48 (ddd, J = 13.7, 5.7, 4.1 Hz, 1H), 3.40 (q, J = 6.9 Hz, 2H), 3.32 (dt, J = 13.7, 5.1 Hz, 1H), 2.77 (t, J = 7.2 Hz, 2H), 2.18 (d, J = 1 Hz, 3H), 1.69 (td, J = 4.4, 1.6 Hz, 1H).^1^C NMR (126 MHz, Chloroform-d): δ= 169.79, 160.07, 156.09, 134.45, 128.57, 125.17, 121.51, 118.57, 114.42, 102.80, 79.45, 45.67, 41.34, 35.35, 17.86, 11.61.
Compound 17 was obtained by general method 1 and 2 from compound 14.

$^1$H NMR (500 MHz, Methanol-d4): $\delta$ = 7.23 – 7.15 (m, 2H), 6.89 (d, $J$ = 8.2 Hz, 1H), 6.80 (d, $J$ = 1.6 Hz, 1H), 4.18 (s, 2H), 3.11 (t, $J$ = 7.9 Hz, 2H), 3.05 (dd, $J$ = 12.7, 4.8 Hz, 1H), 2.87 (dd, $J$ = 9.1, 6.6 Hz, 2H), 2.75 (dd, $J$ = 12.8, 6.2 Hz, 1H), 2.16 (d, $J$ = 1.0 Hz, 3H), 1.65 (ddd, $J$ = 6.2, 4.7, 1.5 Hz, 1H). $^{13}$C NMR (126 MHz, Methanol-d4): $\delta$ = 156.64, 132.82, 132.47, 129.18, 121.41, 119.51, 116.75, 102.93, 55.94, 47.52, 41.99, 33.58, 15.10, 11.17.
NMRs for the molecules synthesized in chapter I
Chapter II: Development of spirocyclopropene, a new chemical biology tool to control cyclopropene reactivity

Introduction

In chapter I, we developed a general method to study neural circuits which represent a certain kind of cell-cell connection that the cells talk with each other by neurotransmitters. However, there are a lot of other kinds of functional cells in brain. They talk with each other by different ways, not just neurotransmitters. Some kinds of cell-cell connections are related to certain neuron degenerative diseases. So a novel method to study functional cell-cell interactions is needed. In order to do that, we try to develop a new kind of bioorthogonal reactions which we can control the reactivity by light or enzyme. My work is trying to design and synthesize that kind of bioorthogonal tools as the start of the whole strategy.

Here I describe the development of a strategy to control cyclopropene reactivity with tetrazines. The ultimate goal of this research will be its application to visualizing neural circuits using lipophilic bioorthogonal tracers that contain a lipid anchor linked to a cyclopropene.

Cyclopropene-tetrazine reaction is one of the most popular bioorthogonal reaction. This kind of click chemistry can react rapidly via inverse-electron-demand Diels–Alder (IED-DA) reactions. The remarkable speed of cyclopropene-tetrazine reaction is very useful for sensitive bio-imaging.
We are trying to control the reactivity of this tracer. However, there is still no technique for controlling the reactivity for this reaction. So now we are focusing on make a ‘turn-on’ biorthogonal tools which we can easily control the reactivity of the reaction.

Lin and co-workers described a spirocyclopropene for reaction with tetrazole in 2016¹⁸. Lin showed that the projection of hydrogens on the exocyclic 4- or 5-membered ring affect the reactivity because of the steric hindrance which inspired us to design a new kind of spirocyclopropene that contain a nitrogen for caging the reactivity. We can attach a bulk group on the nitrogen which can be cleaved by light or enzyme (Figure 8). We think that the bulky group can efficiently cage the reactivity of spirocyclopropene-tetrazine reaction. When we remove that bulky group by enzyme or UV light (Figure 8), the spirocyclopropene can rapidly react with tetrazine. Then we can control the reactivity of the cyclopropene-tetrazine reaction precisely. Since it has a lipid anchor on the molecule, we can directly apply this new tracer to a fixed brain. Because it is a lipophilic molecule, it can diffuse along the cell’s membrane and get to the certain part we want it to go. Now we are still interested in synapse, which connects two neuron cells.

We hoped that the when the tracer reached the synapse, the fluorescence activator is released by a specific protease that is targeted to the synapse by conjugation to an antibody. The cyclopropene then activates the pro-fluorescent lipid’s fluorescence which was quenched by a tetrazine on the connected neuron, which has been uniformly applied throughout the system.

**Synthesis of 3-N-substituted spirocyclopropenes**

We have designed three kinds of spirocyclopropene. At very beginning, we tried to make the spirocyclopropene which has no electron withdrawing group on the exocyclic ring. However,
when we tried to eliminate the bromine from the cyclopropane intermediate, it formed either alkane when the R group was proton or allene when the R group was something else (Figure 10).

So, we designed three series of spirocyclopropene. They all have an electron withdrawing group on the exocyclic ring (Figure 11). We hoped that the electron withdrawing could stabilize the structure of spirocyclopropene. My work focuses on the synthesis of the difluoro-substituted spirocyclopropene.

I started with a five member ring intermediate which can be made in three steps from commercially available starting materials. I used Diethylaminosulfur trifluoride to replace the ketone with two fluorines and then used LAH to reduce the ester to an alcohol. Then I added a 4-Toluenesulfonyl group on the alcohol and used 1, 8-Diazabicyclo [5.4.0] undec-7-ene to do the

![Figure 10: Elimination product of spirocyclopropane with mono bromine](image)

![Figure 11: New series of spirocyclopropene](image)
elimination and obtained alkane. Then I found a method to synthesis the bromo spiro-
cyclopropane. The final step was using t-BuOK to do the elimination of bromo spiro-
cyclopropanes and obtained di-fluoro spirocyclopropene (Figure 12).

When we tested the kinetics of the original di-fluoro spirocyclopropene, we found that it was
unstable in pH 7.4 or even higher. Multiple reports have noted that putting a functional group on
the C1 carbon of
cyclopropene, even a
methyl group could
stabilize the
cyclopropene.

Accordingly, we employed a strategy to functionalize the C1 position to improve stability and
add a synthetic handle for attached biomolecules of interest (Figure 12). Analyzing the stability
of the monomethyl spirocyclopropene revealed that it was stable at pH 7.4 and had good
reactivity with tetrazine.
Synthesis of photoactivatable di-fluoro spirocyclopropene

In the meantime, I attached a light-protected group on the difluorospirocyclopropene. I chose an o-nitrobenzyl protecting group, which can be cleaved by UV light and is widely used in chemical biology\(^\text{19}\) (Figure 14). This bulky group is in ideal position to block the cyclopropene face that tetrazine approaches and should thus inhibit the reaction.

To ensure low reactivity with tetrazine, I dissolved 1 mmol di-fluoro spirocyclopropene, and 0.25 mmol tetrazine in 200 μL PBS solution and tracked the reaction by HPLC. I injected the reaction in HPLC after 3h, 24h, 48h and 7 days. Fortunately, we observed no reaction products or consumption of starting material by HPLC, which indicated a very sluggish reaction between tetrazine and photocaged spirocyclopropene.

In the future work, we will try to get the precise kinetics date about the caged and uncaged spirocyclopropene. Next, we will try to put the enzyme cleavable group on the nitrogen. Then we can control the reactivity by enzyme.

Experiment section

General materials and methods. All chemical reagents were of analytical grade, obtained from commercial suppliers, and used without further purification unless otherwise specified. Rhodium
(II) acetate (Rh₂OAc₄) was gently heated under vacuum until it became a free flowing powder (typically 15–20 s) before using it for reactions. Reactions were monitored by thin layer chromatography (TLC) on pre-coated glass TLC plates (Analtech UNIPLATE™ silica gel HLF w/ organic binder, 250 μm thickness, with UV254 indicator) or by LC/MS (Agilent LC-MSD, direct-injection mode, 1–10 μL, ESI). TLC plates were visualized by UV illumination or developed with either potassium permanganate stain (KMnO₄ stain: 1.5 g KMnO₄, 10 g K₂CO₃ and 1.25 mL of 10% NaOH dissolved in 200 mL H₂O), ceric ammonium molybdate stain (CAM stain: 12 g (NH₄)₆Mo₇O₂₄ • 4H₂O, 0.5 g Ce(NH₄)₂(NO₃)₆ and 15 mL of concentrated H₂SO₄ dissolved in 235 mL H₂O), or ninhydrin stain (1.5 g ninhydrin dissolved in 100 mL of n-BuOH and 3 mL of conc. AcOH). Flash chromatography was carried out using Sorbtech, 60 Å, 40–63 μm or Millipore 60 Å, 35-70 μm silica gel according to the procedure described by Still¹⁵. HPLC was performed using a Shimadzu HPLC (FCV-200AL) equipped with an Agilent reversed phase Zorbax Sb-Aq C18 column (4.6 × 250 mm or 21.2 × 250 mm) fitted with an Agilent stand-alone prep guard column. NMR spectra (1H and 13C) were obtained using a 400, 500, or 700 MHz Bruker spectrometer and analysed using Mestrenova 9.0. 1H and 13C chemical shifts (δ) were referenced to residual solvent peaks. High-resolution electrospray ionization (ESI) mass spectra were obtained at the Stony Brook University Institute for Chemical Biology and Drug Discovery Mass Spectrometry Facility with an Agilent LC-UV-TOF spectrometer.
To a solution of β-alanine (20.0 g, 224.49 mmol, 1 eq) in 2M NaOH (200 mL) and THF (200 mL) was added Boc₂O (49.98 g, 228.98 mmol, 1.02 eq). The reaction mixture was stirred at rt for 16 h, concentrated in vacuo to remove THF, and diluted with DCM (50 mL). The organic layer was discarded and the aqueous layer was acidified to pH 1-2 using 2M HCl. The aqueous layer was washed with EtOAc (3× 75 mL) and the combined organic layers were dried over anhydrous Na₂SO₄, and concentrated in vacuo to obtain an oil which solidified upon cooling to give 1 as a white powder (42.2 g, quantitative). Rf = 0.1-0.5 (50% EtOAc/hexanes, visualized w/ Ninhydrin stain). ¹H NMR (25:75 % mixture of rotamers, 500 MHz, CDCl₃): δ= 11.68 (s, 1H), 6.32 (s, 0.27H), 5.16 (s, 0.62H), 3.39–3.32 (m, 2H), 2.56–2.51 (m, 2H), 1.50–1.30 (m, 9H). ¹³C NMR (rotamers, 126 MHz, CDCl₃): δ= 177.53, 176.47, 157.69, 156.11, 81.25, 79.79, 37.25, 35.99, 34.54, 28.45. MS (ESI): Calcd for C₈H₁₅NO₄ [M]+: 189.1, found: 134.1 [M-C(CH₃)₃+2H]⁺, 190.1 [MH]⁺.
2 was synthesized based on a modification to a previously described strategy. To a suspension of 1 (19.78 g, 104.50 mmol, 1 eq) in THF (200 mL) was added CDI (20.49 g, 125 mmol, 1.2 eq) and the mixture was stirred at rt for 4 h during which it turned homogenous. To this activated ester (Rf = 0.25, 50% EtOAc/hexanes, visualized w/ UV) was added a mixture of MgCl₂ (9.95 g, 104.50 mmol, 1 eq) and name (32.64 g, 209 mmol, 2 eq) in one portion. The suspension was stirred at rt for 16 h, quenched with water, and concentrated in vacuo to remove THF. The reaction mixture was then diluted with DCM (150 mL) and 1M HCl (150 mL), and stirred at rt for 15 min to dissolve the white solid. The aqueous layer was acidified to pH 1-2 using 1M HCl and extracted with DCM. The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄ and concentrated in vacuo to obtain a crude pale yellow oil which was used without further purification (26.2 g). Rf = 0.31 (30% EtOAc/hexanes, visualized w/ UV). 

\[
\begin{align*}
&{^1}H \text{ NMR (16:84 % mixture of rotamers, 500 MHz, CDCl}_3): \delta = 5.88 \text{ (s, 0.16 H), 5.21 \text{ (s, 0.82 H), 3.54} \text{ (s, 2H), 3.51} \text{ (s, 3H), 3.15 (q, J = 6.1 Hz, 2H), 2.59 (t, J = 6.1 Hz, 2H), 1.25–1.20} \text{ (m, 9H).} \\
&{^{13}}C \text{ NMR (rotamers,126 MHz, CDCl}_3): \delta = 202.22, 168.89, 155.96, 79.27, 52.14, 48.74, 42.71, 40.76, 28.11. \text{ MS (ESI): Calcd for C}_{11}H_{19}NO_5 [M]^+: 245.1, found: 146.1 [M-Boc+2H]^+, 190.1 [M-C(CH}_3)_{3+2H}]^+, 246.1 [MH]^+. }
\end{align*}
\]

To an ice-cold solution of TsCl (10.0 g, 52.46 mmol, 1.0 eq) in acetone (100 mL) and water (50 mL) was added NaN₃ (3.58 g, 55.09 mmol, 1.05 eq) and the reaction was allowed to warm to rt over 4 h. Reaction was concentrated in vacuo at 27 °C to remove acetone. The aqueous layer was washed with DCM (3×50 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated in vacuo to obtain 3 as a transparent oil which solidified upon freezing (10.3 g,
To a solution of crude β-ketoester 3 (26.2 g, 106.8 mmol, 1 eq) in MeCN (400 mL) was added tosyl azide (21.42 g, 108.9 mmol, 1.02 eq). Et₃N (44.4 mL, 320.4 mmol, 3 eq) was added dropwise and the mixture was stirred at rt for 2 h. The reaction mixture was concentrated in vacuo, and diluted with DCM and water. The organic layer was collected and the aqueous layer was further washed with DCM. The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, concentrated in vacuo, and purified by flash chromatography (180 g silica, 30% ethyl acetate/hexanes (v/v)) to obtain 4 as a yellow oil (27.0 g, 95.2 % over two steps). Rf = 0.43 (30% EtOAc/hexanes, visualized w/ UV). ¹H NMR (500 MHz, CDCl₃): δ= 5.17 (t, J = 6.2 Hz, 1H), 3.51 (s, 3H), 3.08 (q, J = 6.2 Hz, 2H), 2.71 (t, J = 6.2 Hz, 2H), 1.07 (s, 9H). ¹³C NMR (126 MHz, CDCl₃): δ= 190.74, 160.95, 155.24, 78.09, 75.30, 51.60, 40.15, 35.03, 27.71. MS (ESI): Calcd for C₁₁H₁₇N₃O₅ [M]+: 271.1, found: 272.1 [MH]+, 294.1 [MNa]+.

To a solution of 4 (25.5 g, 94.06 mmol, 1 eq) in dry toluene (350 mL) was added Rh₂OAc₄ (208 mg, 0.47 mmol, 0.005 eq) and the mixture was stirred at 90 °C for 1 h. The reaction mixture was concentrated in vacuo and passed through silica gel (60 g) using ether to obtain 5 as an oil which solidified upon cooling (20.85 g, 91.2%). Rf = 0.27 (30% EtOAc/hexanes, visualized w/ UV). ¹H NMR (33:67 % mixture of rotamers, 700 MHz, CDCl₃): δ= 4.14 (m, 1H), 3.55–3.48 (m, 1H), 3.45–3.39 (m, 4H), 2.43–2.36 (m, 1H), 2.35–2.31 (m, 1H), 2.20–2.17 (m, 1H), 1.95–1.81 (m, 1H), 1.76–1.69 (m, 1H), 1.64–1.56 (m, 1H), 1.55–1.48 (m, 1H), 1.36–1.30 (m, 1H), 1.28–1.20 (m, 1H), 1.18–1.12 (m, 1H), 1.11–1.03 (m, 1H), 1.02–0.95 (m, 1H), 0.95–0.88 (m, 1H), 0.88–0.81 (m, 1H), 0.81–0.74 (m, 1H), 0.74–0.67 (m, 1H), 0.67–0.60 (m, 1H), 0.60–0.53 (m, 1H), 0.53–0.46 (m, 1H), 0.46–0.40 (m, 1H), 0.40–0.33 (m, 1H), 0.33–0.26 (m, 1H), 0.26–0.20 (m, 1H), 0.20–0.13 (m, 1H), 0.13–0.06 (m, 1H), 0.06–0.00 (m, 1H).
1.14–1.06 (2×s, 9H). $^{13}$C NMR (rotamers, 175 MHz, CDCl$_3$): δ= 204.04, 203.51, 166.31, 166.03, 153.42, 153.07, 80.04, 65.05, 64.65, 52.16, 52.12, 41.74, 41.07, 36.40, 35.70, 27.57, 27.44. MS (ESI): Calcd for C$_{11}$H$_{17}$NO$_5$ [M$^+$]: 243.1, found: 144.1 [M-Boc+2H$^+$], 188.1 [M-C(CH$_3$)$_3$+2H$^+$], 244.1 [MH$^+$], 487.2 [2M+H$^+$].

6 was synthesized based on a modification of a recently described strategy. 5 (6.5 g, 26.74 mmol, 1 equiv) was added to a flame dried flask under argon and cooled down to 0 °C. DAST (10.6 mL, 80.21 mmol, 3 equiv) was added dropwise using syringe and the resulting solution was allowed to warm to rt overnight. The yellow-orange solution was cooled down to 0°C, diluted with DCM, and quenched using dropwise addition of a saturated NaHCO$_3$ (~200 mL) until pH 8-9. The mixture was stirred for 30 min at 0°C and the resulting biphasic mixture was separated. The aqueous layer was further extracted with DCM. The combined organic layers were washed with brine, dried over anhydrous Na$_2$SO$_4$, concentrated in vacuo, and purified by flash chromatography (100 g silica, 10% ethyl acetate/hexanes (v/v)) to obtain 6 as a pale-yellow oil (4.3 g, 61%). Rf = 0.27 (10% EtOAc/hexanes, visualized w/ KMnO$_4$). (4.51 g, 16.16 mmol, 64% yield). $^1$H NMR (50:60 % mixture of rotamers, 500 MHz, CDCl$_3$): δ= 4.50–4.38 (m, 1H), 3.77 (s, 3H), 3.77–3.68 (m, 1H), 3.55–3.47 (m, 2H), 2.51–2.27 (m, 2H), 1.40 (2×s, 9H). $^{13}$C NMR (126 MHz, CDCl$_3$) δ= 167.99, 167.96, 167.92, 167.89, 153.77, 153.16, 128.68, 128.01, 126.65, 125.99, 124.63, 124.00, 81.22, 81.15, 65.41, 65.17, 64.93, 64.83, 64.59, 64.35, 52.90, 52.75, 43.48, 43.44, 42.94, 42.91, 33.62, 33.43, 33.25, 33.02, 32.84, 32.65, 28.33, 28.21. $^{19}$F NMR (376 MHz, CDCl$_3$): δ= (-94.24)–(-95.29) (m, 1F), (-105.89)–(-108.12) (m, 1F). MS (ESI): Calcd for C$_{11}$H$_{17}$F$_2$NO$_4$, 265.1; found, 166.1 [M-Boc+2H$^+$], 210.1 [M-C(CH$_3$)$_3$+2H$^+$], 266.1 [MH$^+$].
To a solution of 6 (540 mg, 2.03 mmol, 1 eq) in anhydrous THF (5 mL) at 0 °C was added LAH (85 mg, 2.24 mmol, 1.1 eq) in portions. The resulting suspension was stirred for 30 min at 0 °C. The reaction was quenched with ice cold water, diluted with DCM (10 mL) and separated. The organic layer was collected and the aqueous layer was further washed with DCM. The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, concentrated in vacuo, and purified by flash chromatography (11 g silica, 20% EtOAc/hexanes (v/v)) to obtain 7 as a colourless oil (474 mg, 99%). A similar reaction starting with 5.0 g of S6 produced 3.35 g of S7 (75% yield). Rf = 0.17 (20% EtOAc/hexanes, visualized w/ KMnO₄ stain).

1H NMR (16:84 % mixture of rotamers, 400 MHz, CDCl₃): δ= 3.98–3.85 (m, 1.5H), 3.85 (s,1H), 3.69–3.67 (m, 1H), 3.51–3.44 (m, 1.5H), 2.57–2.22 (m, 2H), 1.44–1.43 (m, 9H). 13C NMR (rotamers, 100 MHz, CDCl₃): δ= 155.88, 155.57, 154.23, 153.39, 128.73, 126.75, 124.72, 99.60, 99.02, 81.15, 80.92, 64.34, 64.12, 63.90, 62.73, 62.50, 61.29, 60.49, 60.05, 49.13, 48.99, 43.48, 42.87, 33.29, 33.11, 32.93, 28.47, 28.40. MS (ESI): Calcd for C₁₀H₁₇F₂NO₃ [M]⁺: 237.1, found: 138.1 [M-Boc+2H]⁺, 182.1 [M-C(CH₃)₃+2H]⁺, 238.1 [MH]⁺, 260.1 [MNa]⁺.
To a solution of 7 (5.20 g, 21.93 mmol, 1 eq) in DCM (50 mL) was added TsCl (5.01 g, 26.32 mmol, 1.2 eq), Et3N (2.88 g, 28.52 mmol, 1.3 eq), and DMAP (53 mg, 0.43 mmol, 0.02 equiv). The reaction mixture was then heated to 45 °C and stirred at this temperature for 16 h. The reaction mixture was diluted with water and the crude product extracted with DCM (4×30 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, concentrated in vacuo, and purified by flash chromatography (130 g silica, 10% EtOAc/hexanes (v/v)) to obtain 8 as a colourless oil (7.3 g, 85%). Rf = 0.37 (20% EtOAc/hexanes, visualized w/ UV). 1H NMR (47:53 % mixture of rotamers, 500 MHz, CDCl3): δ = 7.70–7.67 (m, 1H), 7.28 (d, J = 8.5 Hz, 2H), 5.14 (m, 0.34H), 4.56–4.36 (m, 1H), 4.27–4.25 (m, 0.32H), 4.11–4.04 (m, 1H), 4.00–3.93 (m, 1H), 3.87–3.75 (m, 0.39H), 3.47–3.33 (m, 1.25H), 2.68–2.11 (m, 1.30H), 1.35 (m, 9H).

13C NMR (rotamers, 126 MHz, CDCl3): δ = 153.93, 153.65, 153.55, 153.27, 153.10, 152.90, 151.74, 151.46, 144.98, 144.86, 144.79, 144.60, 132.58, 132.54, 132.27, 129.76, 129.70, 129.63, 127.55, 127.52, 127.50, 80.77, 80.49, 80.41, 80.09, 66.37, 66.35, 65.69, 65.67, 65.58, 65.24, 60.83, 60.59, 60.37, 58.37, 58.14, 48.78, 48.73, 48.28, 48.23, 42.77, 42.30, 3.98, 32.77, 32.34, 32.15, 31.98, 28.00, 27.91, 21.26. 13C DEPT-135 NMR (rotamers, 126 MHz, CDCl3): δ = (up) 129.76, 129.70, 60.97, 60.74, 60.50, 58.51, 58.28, 42.91, 42.43, 28.14, 28.05, 21.40. (down) 66.51, 66.50, 65.83, 65.79, 65.75, 48.92, 48.87, 48.42, 48.37, 33.30, 33.13, 32.95, 32.48, 32.28, 32.10. HRMS (ESI): Calcd for C17H23F2NO5S [M+NH4]^+: 409.1603, found: 409.1602.

To a solution of 8 (1.10 g, 2.81 mmol, 1 eq) in glyme (30 mL) was added NaI (1.35 g, 9 mmol, 3 eq), and DBU (915 mg, 6 mmol, 2 eq). The reaction mixture was refluxed for 4 h, diluted with water (20 mL), and extracted with Et2O (3×30 mL). The combined organic layers were washed with brine, dried
over anhydrous Na$_2$SO$_4$, concentrated in vacuo, and purified by flash chromatography (130 g silica, 10% EtOAc/hexanes (v/v)) to obtain x as a pale-yellow oil (0.51 g, 82.3%). We found the alkene to be unstable on silica and, therefore, used it without the flash chromatography for future production of 9. Rf = 0.88 (20% EtOAc/hexanes, visualized w/ UV). $^1$H NMR (500 MHz, CDCl$_3$): $\delta$= 5.56 (br s, 1H), 4.90 (s, 1H), 3.67 (t, $J$ = 7.1 Hz, 2H), 2.31 (m, 2H), 1.52 (s, 9H). $^{13}$C NMR (126 MHz, CDCl$_3$): $\delta$= 152.10, 140.35, 125.06, 123.14, 121.18, 92.84, 83.94, 43.79, 31.97, 31.76, 31.57, 28.40. HRMS (ESI): Calcd for C$_{10}$H$_{15}$F$_2$NO$_5$ [M+H]$^+$: 220.1144, found: 220.1148.

To a solution of 9 (2.19 g, 10.00 mmol, 1 eq) in CHBr$_3$ (1.8 mL, 5.1 g, 20.00 mmol, 2 eq) and DCM (3 mL) was added CTAB (0.364 g, 1.00 mmol, 0.1 eq) and the mixture was stirred vigorously. To this was added NaOH (18 mL, 50% w/v) dropwise. The brown-black reaction mixture was stirred for 24 h at rt. To this reaction was added additional CHBr$_3$ and CTAB based on TLC and the process was repeated until complete consumption of reactant. Complete consumption of reactant was a necessity as the product have same Rf as the reactant. Upon completion, the reaction mixture was diluted with DCM and water. The organic layer was collected, washed with brine and concentrated under reduced pressure. The crude obtained was purified by flash chromatography (120 g silica, 2.5% EtOAc/hexanes (v/v)) to obtain 10 as a light-yellow oil (2.07 g, 65%) Rf = 0.28 (2.5% EtOAc/hexanes, visualized w/ UV). $^1$H NMR (700 MHz, CDCl$_3$): $\delta$= 3.86 (br s, 1H), 3.59 (m, 1H), 2.51–2.45 (m, 1H), 2.40–2.32 (m, 1H), 2.27 (d, $J$ = 9.9 Hz, 1H), 1.57–1.52 (m, 1H), 1.45 (s, 9H). $^{13}$C NMR (176 MHz, CDCl$_3$): $\delta$= 153.62, 124.93, 123.44, 122.04, 81.50, 52.66, 52.51, 52.48, 52.32, 31.74, 28.44, 22.81, 14.28. HRMS (ESI): Calcd for C$_{11}$H$_{15}$Br$_2$F$_2$NO$_2$ [M+Na]$^+$: 411.9330, found: 411.9306.
To an ice-cold solution of 10 (800 mg, 2 mmol, 1 eq) in anhydrous THF (6.0 mL) under N2 was added 3M EtMgBr (0.8 mL, 2.4 mmol, 1.2 eq) and Ti(OiPr)$_4$ (60 mg, 0.064 mL, 0.2 mmol, 0.1 eq) and the mixture was stirred at the same temperature for 1 hour. The reaction was quenched by ice-water and diluted with DCM. The organic layer was collected and the aqueous layer was further washed with DCM. The combined organic layers were dried over anhydrous Na$_2$SO$_4$, concentrated in vacuo, and purified by flash chromatography (120 g silica, 2.5% EtOAc/hexanes (v/v)) to give crude 11 as a mixture of diastereomers which was used for the next step without further purification. Rf = 0.50 (5% EtOAc/hexanes, visualized w/ UV). $^1$H NMR (500 MHz, CDCl$_3$): $\delta=$ 3.89 (br s, 1H), 3.62 (t, $J = 7.4$ Hz, 0.56H), 3.55 (td, $J = 10.5$, 4.5 Hz, 0.78H), 3.21 (m, 0.65H), 2.50–2.39 (m, 0.82H), 2.37–2.21 (m, 1.53H), 1.75 (t, $J = 8.8$ Hz, 0.79H), 1.54 (2x, 1.16 H), 1.46 (2x, 9H). MS (ESI): Calcd for C$_{11}$H$_{16}$BrF$_2$NO$_2$ [M]+: 311.0, found: 256.0 [M-C(CH$_3$)$_3$+2H]+, 258.1 [M+2-C(CH$_3$)$_3$+2H]$,^+$, 312.0 [MH]$^+$, 314.0 [M+2+H]$^+$.

The crude 11 (amount) was dissolved in anhydrous THF (5.0 mL) and cooled down to 0 °C. To this solution was added KOTBu (0.72 mmol, 88mg, 1.2eq) at 0 °C and the reaction was stirred at the same temperature for 1 h. The reaction was quenched with water and diluted with DCM. The organic layer was collected and the aqueous layer was further washed with DCM. The combined organic layers were dried over anhydrous Na$_2$SO$_4$, concentrated in vacuo, and purified by flash chromatography (100 g silica, 20% EtOAc/hexanes(v/v)) to obtain pure 12 as a pale-yellow oil (140 mg, 30% combine 2 step). Rf = 0.23 (5% EtOAc/hexanes, visualized w/ KMnO$_4$). $^1$H NMR (500 MHz, CDCl$_3$): $\delta=$ 7.28 (br s, 2H), 3.56 (t, $J = 6.0$ Hz), 2.35 (m, 2H), 1.40 (s, 9H). $^{13}$C NMR (126 MHz, CDCl$_3$): $\delta=$ 154.20, 126.57, 124.63, 122.68, 111.59, 80.12, 47.82, 47.55, 47.27,
41.02, 32.14, 31.95, 31.75, 28.59. HRMS (ESI): Calcd for C<sub>11</sub>H<sub>15</sub>F<sub>2</sub>NO<sub>2</sub> [M+Na]<sup>+</sup>: 411.9330, found: 411.9306.

To a solution of 12 (40 mg, 0.17 mmol) in DCM (2.0 mL) at 0 °C was added TFA (0.4 mL). After stirring the reaction at the same temperature for 1 h, it was concentrated in vacuo (<25 °C) to obtain pure 13 as a TFA salt (41 mg, 41%).<sup>1</sup>H NMR (700 MHz, CD<sub>3</sub>OD): δ = 7.79 (s, 2H), 3.53 (t, J = 4.3 Hz, 2H), 2.69 (m, 2H).<sup>13</sup>C NMR (176 MHz, CD<sub>3</sub>OD): δ = 161.45, 161.24, 161.02, 160.81, 125.70, 124.31, 122.92, 119.69, 118.04, 116.41, 114.77, 108.98, 54.81, 40.84, 40.82, 40.79, 34.17, 34.02, 33.88, 28.67. HRMS (ESI): Calcd for C<sub>6</sub>H<sub>7</sub>F<sub>2</sub>N [M+Na]<sup>+</sup>: 411.9330, found: 411.9306.

To a solution of 13 (17 mg, 0.07 mmol, 1eq) in CHCl<sub>3</sub>/Et<sub>2</sub>O (2 mL, 9:1 v/v) at 0 °C was added NaHCO<sub>3</sub> (13.4 mg, 0.16 mmol, 2.3 eq) and 4,5-Dimethoxy-2-nitrobenzyl chloroformate (23.15 mg, 0.08 mmol, 1.2 eq) respectively. The reaction was allowed to warm to rt and stirred for 15 h. It was then diluted with DCM and water. The organic layer was collected and the aqueous layer was further washed with DCM. The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated in vacuo, and purified by flash chromatography to give crude S14 (100 g silica, 20% EtOAc/hexanes(ν/ν)). It was further purified by HPLC.<sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>): δ = 7.68 (s, 1H), 7.32 (s, 2H), 6.93 (s, 1H), 5.45 (s, 2H), 3.97 (s, 3H), 3.95 (s, 3H), 3.67 (t, J = 6.0 Hz, 2H), 2.41 (m, 2H).<sup>13</sup>C NMR (176 MHz, CDCl<sub>3</sub>): δ = 153.44, 148.39, 140.29, 127.51, 111.45, 110.90, 108.40, 63.74, 56.56, 53.57, 41.21, 32.11, 31.92, 31.74, 29.58, 29.50, 29.39, 29.22. HRMS (ESI): Calcd for C<sub>16</sub>H<sub>16</sub>F<sub>2</sub>N<sub>2</sub>O<sub>6</sub> [M]<sup>+</sup>: 377.0976, found: 411.9306.
To a solution of LiHDMS (200 μL, 1M in THF, 9.2 mmol, 1.5 eq) in 1 mL dry THF was added 12 (30 mg, 0.12 mmol, 1 eq) under N\textsubscript{2} at – 30°C. After 5 min, 13 μL Me\textsubscript{2}SO\textsubscript{4} (1.05 eq) was added to the solution. After 30 min, the reaction was quenched with water and diluted with DCM. The organic layer was collected and the aqueous layer was further washed with DCM. The combined organic layers were dried over anhydrous Na\textsubscript{2}SO\textsubscript{4}, concentrated in vacuo, and purified by flash chromatography. (8 g silica, 3% EtOAc/hexanes(v/v)) to obtain 16 20 mg (60%).

To a solution of 15 (40 mg, 0.17 mmol) in DCM (2.0 mL) at 0 °C was added TFA (0.4 mL). After stirring the reaction at the same temperature for 1 h, it was concentrated in vacuo (<25 °C) to obtain pure 16 as a TFA salt. \textsuperscript{1}H NMR (500 MHz, Methanol-\textit{d}4): \(\delta = 7.19\) (dp, \(J = 3.2, 1.1\) Hz, 1H), 3.52 (t, \(J = 7.5\) Hz, 2H), 2.67 (ttd, \(J = 12.7, 7.4, 1.5\) Hz, 2H), 2.29 (d, \(J = 1.1\) Hz, 3H). \textsuperscript{13}C NMR (126 MHz, CD\textsubscript{3}OD): \(\delta = 118.35, 118.31, 118.28, 100.47, 100.44, 100.43, 100.40, 40.80, 40.77, 40.74, 34.42, 34.22, 34.01, 8.65\). Peaks for two quaternary carbons (CO and CF\textsubscript{2}) and TFA were not observed. HRMS (ESI): Calcd for C\textsubscript{7}H\textsubscript{9}F\textsubscript{2}N [M+H]\textsuperscript{+}: 146.0776, found: 1
NMRs for the molecules synthesized in chapter II
$^{19}\text{F CPD NMR (376 MHz)}$

![NMR Spectrogram](image)
have carbon
Reference


9219 (2012).


